Key market drivers of the Insulin Pen and Pump market include the rising prevalence of diabetes, advancements in insulin delivery technologies ...

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

If you or your loved one relies on insulin, you will be able to buy Novo Nordisk's products for $35 per month due to a ...

Subcutaneous Drug Delivery Devices market Growth Fueled by Chronic Diseases and Technological Innovation Akash Anand SNS Insider Pvt. Ltd 415-230-0044 email us here Visit us on social media: Facebook ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Manufactured by Novo Nordisk, semaglutide is the newest in a family of glucagon ... blood glucose levels by mimicking the GLP ...

“Improving prescription drug affordability for Medicare enrollees is the core of the Inflation Reduction Act, and the next ...

In 2023, the global disposable pen injectors market is expected to be worth USD 25.5 billion. The market is expected to reach USD 54.4 billion by 2033, expanding at a 7.9% CAGR throughout the forecast ...

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs.

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...